In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Panbela Therapeutics (PBLA – Research Report), with a price target of $16.00. The company’s shares opened today at $2.20.
According to TipRanks, Pantginis is an analyst with an average return of -3.6% and a 36.07% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Panbela Therapeutics, Onconova Therapeutics, and Celldex.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Panbela Therapeutics with a $16.00 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $1,680.00 and a one-year low of $1.80. Currently, Panbela Therapeutics has an average volume of 255.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sun BioPharma Inc. is a clinical-stage drug development company, which engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The company was founded by Michael Cullen and Thomas Neenan on September 21, 2011 and is headquartered in Waconia, MN.
Read More on PBLA:
- Panbela Announces Preliminary Safety Analysis for ASPIRE Trial
- Panbela Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis
- Panbela announces PACES S0820 Phase II trial passes futility analysis
- Panbela Therapeutics announces presentation on results for CPP-1X
- Panbela Announces Poster Presentation at the Endocrine Society Meeting: Polyamine Inhibition and β-Cell Preservation in Recent Onset Type 1 Diabetes
